Financial Performance - The company's revenue for Q1 2023 was CNY 193,788,912.58, representing a 5.73% increase compared to CNY 183,290,412.29 in the same period last year[5]. - Net profit attributable to shareholders decreased by 3.51% to CNY 51,985,920.77 from CNY 53,875,611.94 year-on-year[5]. - The net profit after deducting non-recurring gains and losses fell by 11.88% to CNY 46,808,747.53 compared to CNY 53,120,767.73 in the previous year[5]. - The total operating revenue for Q1 2023 was CNY 193,788,912.58, an increase of 5.6% compared to CNY 183,290,412.29 in Q1 2022[25]. - The net profit for Q1 2023 was CNY 51,674,794.42, a decrease of 4.1% from CNY 53,874,484.71 in Q1 2022[26]. - The total comprehensive income attributable to the parent company is CNY 51,876,683.00, down from CNY 54,106,652.71, reflecting a decline of approximately 4.3%[27]. - Basic and diluted earnings per share for Q1 2023 are both CNY 0.22, compared to CNY 0.30 in the previous period, indicating a decrease of 26.7%[27]. Assets and Liabilities - The company's total assets increased by 7.04% to CNY 2,182,265,103.71 from CNY 2,038,804,786.88 at the end of the previous year[5]. - The total liabilities as of March 31, 2023, were CNY 250,024,516.91, compared to CNY 184,843,822.55 at the start of the year[23]. - The company's cash and cash equivalents decreased to CNY 553,119,978.27 from CNY 806,786,386.60 at the beginning of the year[21]. - The company's inventory increased to CNY 93,157,668.83 from CNY 80,523,332.56 at the beginning of the year, indicating a potential increase in production or sales[22]. Cash Flow - Cash flow from operating activities decreased by 2.27% to CNY 43,734,808.96 compared to CNY 44,750,344.20 in the previous year[5]. - Cash inflow from operating activities totals CNY 187,555,195.15, an increase from CNY 167,719,799.27, representing a growth of 11.0%[30]. - The net cash flow from operating activities is CNY 43,734,808.96, slightly down from CNY 44,750,344.20, a decrease of 2.3%[30]. - Cash outflow from investing activities is CNY 723,535,880.95, significantly higher than CNY 12,493,985.79 in the previous period, indicating increased investment activity[30]. - The net cash flow from investing activities is -CNY 296,882,888.97, compared to -CNY 12,493,485.79, reflecting a larger cash outflow[30]. - The net cash flow from financing activities is -CNY 516,082.76, a decrease from CNY 1,060,775,223.32 in the previous period, indicating reduced financing activity[31]. - The ending cash and cash equivalents balance is CNY 553,069,978.27, down from CNY 1,229,499,447.67, a decline of 55.0%[31]. Research and Development - Research and development expenses surged by 141.08% to CNY 15,898,325.39 from CNY 6,594,626.38 in the same period last year, indicating increased investment in R&D[12]. - Research and development expenses for Q1 2023 were CNY 15,898,325.39, significantly higher than CNY 6,594,626.38 in Q1 2022, reflecting a focus on innovation[26]. - The company has ongoing research and development efforts, although specific new products or technologies were not detailed in the provided content[18]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 9,519[14]. - Major shareholder Zheng Hanjie holds 20.77% of shares, totaling 49,098,900 shares[14]. - Major shareholder Sun Weiwen holds 15.56% of shares, totaling 36,787,150 shares[14]. - The total number of restricted shares at the beginning of the period was 182,722,522, with 73,558,710 shares released during the period[17]. - The company has a total of 109,163,812 restricted shares remaining at the end of the period[17]. - The top ten shareholders hold a significant portion of the company's equity, with the largest shareholder holding over 20%[14]. - The company has established relationships among major shareholders, indicating potential coordinated actions[15]. Acquisitions and Market Expansion - The company plans to acquire 50% equity of Jiangsu Bochuangyuan Biopharmaceutical Technology Co., Ltd[18]. - The company completed the acquisition of a 50% stake in Jiangsu Bochuangyuan Biopharmaceutical Technology Co., Ltd. for CNY 200 million, enhancing its product pipeline[19]. - The company is exploring market expansion opportunities through acquisitions and partnerships[18]. Goodwill - The company reported a significant increase in goodwill by 634.24% to CNY 200,643,602.10 due to acquisitions made during the reporting period[9]. - The company reported a significant increase in goodwill to CNY 200,643,602.10 from CNY 27,326,563.93, indicating potential acquisitions or investments[22].
泰恩康(301263) - 2023 Q1 - 季度财报